Status:
COMPLETED
Subclinical Cardiovascular Disease in Psoriatic Disease
Lead Sponsor:
NYU Langone Health
Conditions:
Cardiovascular Diseases
Myocardial Infarction
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this st...
Detailed Description
Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of CVD mortality b...
Eligibility Criteria
Inclusion
- Subjects with a history of moderate to severe psoriatic disease
- Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease
Exclusion
- Unable to speak Spanish or English
- Active smoking (within the past year)
- Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis
- Known active cancer receiving treatment
- Pregnancy
- Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600)
- A history of severe bleeding or bleeding disorders
- Current medication use which interact with either aspirin or atorvastatin
- Chronic kidney disease (CrCl \< 30ml/min)
- Congestive heart failure
- Currently taking aspirin or a statin.
- NSAID use within the past 48 hours
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03228017
Start Date
August 1 2017
End Date
April 1 2019
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016